Total Payments
$301,200
2024 Payments
$95.62
Companies
28
Transactions
134
Medicare Patients
5,588
Medicare Billing
$982,811
Payment Breakdown by Category
Research$270,675 (89.9%)
Other$21,817 (7.2%)
Travel$3,894 (1.3%)
Food & Beverage$3,088 (1.0%)
Consulting$1,600 (0.5%)
Education$127.48 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $270,675 | 5 | 89.9% |
| Honoraria | $10,997 | 6 | 3.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,820 | 10 | 3.6% |
| Travel and Lodging | $3,894 | 16 | 1.3% |
| Food and Beverage | $3,088 | 92 | 1.0% |
| Consulting Fee | $1,600 | 3 | 0.5% |
| Education | $127.48 | 2 | 0.0% |
Payments by Type
Research
$270,675
5 transactions
General
$30,526
129 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $270,675 | 5 | $0 (2022) |
| Allergan, Inc. | $8,481 | 37 | $0 (2020) |
| TETRAPHASE PHARMACEUTICALS, INC. | $7,979 | 9 | $0 (2019) |
| The Medicines Company | $6,392 | 10 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $6,122 | 21 | $0 (2020) |
| ABBVIE INC. | $173.99 | 7 | $0 (2024) |
| ViiV Healthcare Company | $170.34 | 8 | $0 (2021) |
| Vertiflex, Inc. | $155.79 | 3 | $0 (2018) |
| Astellas Pharma US Inc | $140.52 | 3 | $0 (2018) |
| Melinta Therapeutics, LLC | $138.05 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $95.62 | 4 | Insmed, Inc. ($44.60) |
| 2023 | $15.42 | 1 | Melinta Therapeutics, LLC ($15.42) |
| 2022 | $4,883 | 11 | Eli Lilly and Company ($4,577) |
| 2021 | $22,555 | 6 | Eli Lilly and Company ($22,452) |
| 2020 | $244,300 | 6 | Eli Lilly and Company ($243,645) |
| 2019 | $10,866 | 33 | TETRAPHASE PHARMACEUTICALS, INC. ($7,979) |
| 2018 | $8,256 | 41 | Allergan Inc. ($5,367) |
| 2017 | $10,229 | 32 | The Medicines Company ($6,392) |
All Payment Transactions
134 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $22.76 | General |
| Category: Respiratory | ||||||
| 11/05/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO, AVYCAZ | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/24/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $21.84 | General |
| Category: Respiratory | ||||||
| 02/01/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $27.70 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 12/10/2023 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Vabomere | Food and Beverage | In-kind items and services | $15.42 | General |
| Category: ANTIFUNGALS | ||||||
| 12/02/2022 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/16/2022 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $14.89 | General |
| Category: ANTIBIOTIC | ||||||
| 09/13/2022 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $33.51 | General |
| Category: Infections and Infectious Diseases | ||||||
| 09/03/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $21.86 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/29/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $33.28 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/22/2022 | Melinta Therapeutics, LLC | Kimyrsa (Drug) | Food and Beverage | In-kind items and services | $79.06 | General |
| Category: ANTIBIOTICS | ||||||
| 05/04/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $28.49 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/27/2022 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $30.65 | General |
| Category: Infections and Infectious Diseases | ||||||
| 04/13/2022 | MAYNE PHARMA INC. | — | Food and Beverage | In-kind items and services | $19.29 | General |
| 01/11/2022 | Eli Lilly and Company | — | — | In-kind items and services | $4,577.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 01/04/2022 | Janssen Pharmaceuticals, Inc | — | Education | In-kind items and services | $28.48 | General |
| 10/04/2021 | AbbVie Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $28.35 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/20/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $23.90 | General |
| Category: HIV | ||||||
| 06/28/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $28.28 | General |
| Category: HIV | ||||||
| 02/06/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/26/2021 | Eli Lilly and Company | — | — | In-kind items and services | $11,458.66 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
| 01/26/2021 | Eli Lilly and Company | — | — | In-kind items and services | $10,993.83 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | ||||||
| 09/08/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $242,090.00 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
| 08/14/2020 | Merck Sharp & Dohme Corporation | ZINPLAVA (Biological) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/31/2020 | Merck Sharp & Dohme Corporation | ZINPLAVA (Biological) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $255,104 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | Eli Lilly and Company | $10,994 | 1 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $4,577 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,360 | 2,914 | $596,849 | $241,550 |
| 2022 | 12 | 1,378 | 3,063 | $402,277 | $229,587 |
| 2021 | 11 | 1,343 | 3,231 | $417,308 | $246,186 |
| 2020 | 14 | 1,507 | 3,353 | $475,158 | $265,487 |
Total Patients
5,588
Total Services
12,561
Medicare Billing
$982,811
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 408 | 1,577 | $229,050 | $101,817 | 44.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 258 | 280 | $119,640 | $38,539 | 32.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 170 | 323 | $58,840 | $30,278 | 51.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 161 | 289 | $41,996 | $20,307 | 48.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 79 | 87 | $26,094 | $11,489 | 44.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 64 | 87 | $21,200 | $9,203 | 43.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 35 | 48 | $29,320 | $8,356 | 28.5% |
| G0427 | Telehealth consultation, emergency department or initial inpatient, typically 70 minutes or more communicating with the patient via telehealth | Office | 2023 | 47 | 48 | $30,000 | $6,967 | 23.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 34 | 34 | $13,860 | $5,861 | 42.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 23 | 23 | $3,910 | $3,193 | 81.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 26 | 50 | $11,410 | $2,908 | 25.5% |
| G0408 | Follow-up inpatient consultation, complex, physicians typically spend 35 minutes communicating with the patient via telehealth | Office | 2023 | 18 | 29 | $9,280 | $2,351 | 25.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 20 | 22 | $1,994 | $213.01 | 10.7% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2023 | 17 | 17 | $255.00 | $66.98 | 26.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 438 | 1,721 | $154,890 | $100,827 | 65.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 263 | 263 | $72,325 | $40,428 | 55.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 161 | 370 | $40,700 | $26,655 | 65.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 154 | 302 | $37,060 | $23,746 | 64.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 87 | 98 | $21,560 | $13,344 | 61.9% |
| G0427 | Telehealth consultation, emergency department or initial inpatient, typically 70 minutes or more communicating with the patient via telehealth | Office | 2022 | 63 | 67 | $41,875 | $10,486 | 25.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 28 | 28 | $7,700 | $4,975 | 64.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 17 | 23 | $6,210 | $3,990 | 64.2% |
| G0408 | Follow-up inpatient consultation, complex, physicians typically spend 35 minutes communicating with the patient via telehealth | Office | 2022 | 22 | 40 | $12,800 | $3,263 | 25.5% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2022 | 20 | 20 | $2,000 | $936.22 | 46.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 55 | 56 | $4,032 | $640.17 | 15.9% |
About Dr. Ramesh Nathan, MD
Dr. Ramesh Nathan, MD is a Infectious Disease healthcare provider based in Thousand Oaks, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1215025291.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ramesh Nathan, MD has received a total of $301,200 in payments from pharmaceutical and medical device companies, with $95.62 received in 2024. These payments were reported across 134 transactions from 28 companies. The most common payment nature is "" ($270,675).
As a Medicare-enrolled provider, Nathan has provided services to 5,588 Medicare beneficiaries, totaling 12,561 services with total Medicare billing of $982,811. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Thousand Oaks, CA
- Active Since 10/11/2006
- Last Updated 08/18/2025
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1215025291
Products in Payments
- Xerava (Drug) $7,979
- AVYCAZ (Drug) $7,072
- ORBACTIV (Drug) $6,357
- ZERBAXA (Drug) $4,364
- ZINPLAVA (Biological) $1,600
- DALVANCE (Drug) $1,571
- Superion ISS (Device) $155.79
- PluroGel Burn & Wound Dressings (Device) $83.09
- Kerecis Omega3 Wound (Device) $80.01
- Kimyrsa (Drug) $79.06
- Fetroja (Drug) $64.16
- Arikayce (Drug) $62.51
- TRIUMEQ (Drug) $60.45
- CUVITRU (Biological) $52.46
- CABENUVA (Biological) $52.18
- Gamunex-C (Biological) $48.81
- DIFICID (Drug) $47.87
- VIBATIV (Drug) $44.99
- Vabomere (Drug) $43.57
- BioFire FilmArray (Device) $40.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Thousand Oaks
Sujay Dutta, Md, MD
Infectious Disease — Payments: $6,979
Infectious Disease $6,979
Andrew Ma, Md, MD
Infectious Disease — Payments: $2,446
Infectious Disease $2,446
Philip Mcdonald, M.d, M.D
Infectious Disease — Payments: $1,076
Infectious Disease $1,076
Mark Mazur, Md, MD
Infectious Disease — Payments: $1,046
Infectious Disease $1,046